Palantir's New Healthcare Deal Boosts AI and Data Reach

Palantir Technologies (PLTR) has entered a multi-year partnership with OneMedNet (ONMD) to integrate its Artificial Intelligence Platform (AIP) into OneMedNet's iRWD network, significantly expanding Palantir's presence in the regulated healthcare and life sciences sector. This strategic collaboration reinforces Palantir's strong commercial growth, highlighted by 93% year-over-year U.S. commercial revenue increase and a projected $1.302 billion in U.S. commercial revenue. Despite a consensus analyst price target suggesting a downside, the partnership is seen as justifying the stock's premium valuation, with bullish options activity noted ahead of upcoming earnings, though a recent 10% rise in short interest signals some investor caution.

Analysis

Palantir Technologies (PLTR) has secured a multi-year partnership with OneMedNet (ONMD), integrating its Artificial Intelligence Platform (AIP) to enhance healthcare AI and data analytics for clinical research. This agreement significantly strengthens Palantir's strategic position in the regulated healthcare and life sciences sector, reinforcing its credibility in handling sensitive health data and its role in biomedical data management transformation.

This collaboration further supports Palantir's strong commercial growth, evidenced by a 93% year-over-year increase in U.S. commercial revenue and a 64% rise in customer count. The company projects U.S. commercial revenue to exceed $1.302 billion, representing over 85% growth, with commercial operations now contributing 44% of total revenue, addressing past over-reliance on government contracts.

Despite a consensus analyst price target of $141.28, implying a 20% downside from its current $179.62, the OneMedNet contract is cited as justifying Palantir's premium valuation. Ahead of its November 3rd earnings report, bullish options activity, particularly high call volumes at $180-$200 strikes, suggests investor confidence. However, a 10% increase in short interest over the last month indicates caution, posing a risk if earnings merely meet or miss expectations.

Key Decisions for Investors

• Closely monitor Palantir's Q3 earnings report on November 3rd for commercial revenue growth and forward guidance, which will be a critical catalyst
• Evaluate the long-term strategic value of the OneMedNet partnership in solidifying Palantir's position within the regulated healthcare AI market and its contribution to sustained commercial expansion
• Assess the implications of increased short interest and the analyst consensus downside target, balancing these against the company's strong commercial execution and bullish options activity